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                       Abstract:  
Background Induction of labour (IOL) is an important obstetrical procedure used to 
artificially stimulate labour for specific indications. Because IOL may have adverse 
consequences, there must be clear indications and guidelines on when and how to induce 
labour in patients with specific risk profiles. At Lower Umfolozi District War Memorial 
hospital, Kwazulu-Natal, misoprostol is the main agent for induction of labour. 








1. Study design 
This was a retrospective analysis of 502 patients who underwent IOL for various 
indications.  
2. Method 
 All patients who underwent IOL  and had birth weight of 500 grams or greater, were 
identified and files were collected, information extracted, entered into Microsoft Excel 
data sheet and later transferred to SPSS soft ware for analysis.  





1. Increase in prevalence of IOL. 
2. Potential increase in morbidity for mother and baby. 
3. Few studies for IOL having been done at regional health centres, serving rural 
populations. 




































            
 
 
Results:  The induction rate for this study was 8%.  There were three main indications for 
IOL. These were hypertensive disorders of pregnancy (43.6%), postdates (25.9%) and 
premature rupture of membranes (14.7%).  The main modes of IOL were oral misoprostol 
(63.5%) and vaginal misoprostol (30.3%).  
  The success rates for IOL were 58.3% (N=293) for normal vaginal deliveries and 1.4% 
(N=7)   for assisted vaginal deliveries.  40% of the patients underwent caesarean section 
(CS) (N=202) following IOL.  
Conclusion: The indications for IOL and induction rate in this study were similar to those 






   Induction of labour (IOL) refers to the artificial stimulation of uterine contractions to bring 
about labour after age of viability and before spontaneous onset of labour (2, 3). It is a result of 
risk benefit analysis, in which it is judged that the delivery of the fetus, in the particular 
circumstances, would benefit either the pregnant woman or her fetus, as opposed to the 
continuation of pregnancy(3).  Lower Umfolozi District War Memorial Hospital, in the  province of 
Kwazulu-Natal, South Africa has a high volume of patients, and delivers  approximately 10 000 
women annually. 
1.1 Background and literature review: 
  Induction of labour can be traced to many different cultures. In some ancient cultures, a full 
term pregnant woman would be approached by a horseman, with a threat to trample her so that 
labour might be induced (4).In Greece, a couch was used to hasten labour in a pregnant woman by 
repeatedly lifting and dropping the woman onto the couch(4). Another method was to tie the 
woman to the couch, turning it upright, and repeatedly allowing it to fall to the ground (4). 
  Rates of IOL vary from region to region. In England, since 1989, 20% of labours were induced 
(4). In the U.S, as in many parts of the world, IOL has been rising (5). Factors associated with 
the rising induction rates include: 
• Improvements in assessment fetal well being in pregnancy and labour by ultrasound and 
electronic fetal heart monitoring. 
• The view of many obstetricians that labour should be induced at 41 weeks instead of 42. 




• Patients requesting elective inductions for various reasons, some social and others 
religious. 
• Discovery of new medicines which results in improved rates of successful outcomes of 
IOL. 
    Rates of IOL vary based on patient populations and attitude of doctors. Induced labour 
increases the chance of caesarean sections[C/S], uterine rupture, and premature birth (5-7).     
Mbele et al, in Kalafong, Pretoria studied 558 women, undergoing IOL with oral misoprostol 
prospectively, to determine significant predictors of the success of induction.  These authors 
found three main indications for inductions for IOL in their study, namely hypertensive disorders 
of pregnancy (45%), post dates (22%) and pre-labour rupture of membranes (20.6%).  Vaginal 
deliveries were achieved in 24 hours in 52.4% of patients and C/S rate was 42.1%. The study also 
identified primigravidity, intact membranes and an unfavourable cervix ( poor bishop score)  as 
indicators of an unsuccessful IOL(1). The induction rate for their study was 9.6%. 
  The success of IOL depends on the state of the cervix.  A favourable cervix enhances the 
success of an induction and a scoring system known as Bishop Score was introduced(8).   The 
score is based on five clinical items: dilatation, effacement, station, consistency and position of 
the cervix (9). The score has since been modified in attempting to improve the predictability of a 
successful induction(10). A study on cervical assessment using trans-vaginal ultrasound failed to 
demonstrate any improvement in induction outcome (10, 11). A Bishop score of less than 5 is 
regarded as unfavourable cervix and one above 5 as favourable for IOL (12, 13). In order to 
improve the outcomes of induction, cervical “ripening agents or methods” have been developed.    




                           Ripening of the cervix 
     The process of cervical ripening involves the breakdown of stromal collagen, following 
increased collagenase activity, and a change in the glycosaminoglycans (GAG) and hydration of 
ground substance (14, 15).The changes results from the hormonally mediated biochemical events 
that cause effacement, softening and dilation of cervix. Prostaglandins increase cervical ripening 
by altering the GAG content of the cervix, inhibiting the collagen synthesis and enhancing 
collagenase synthesis by macrophages (15, 16). The oestrogen to progesterone ratio changes 
towards term in pregnancy. Progesterone appears to inhibit cervical ripening, while oestrogen 
promotes phospholipase activity which promotes local prostaglandin synthesis (15). Prostaglandin 
F2α appears to be important in relation to contraction of the uterine myometrium and PGE2 is 
involved in cervical ripening (16).The main source of PGF2α is the decidua and PGE2 is derived 
from the amnion.  Between the decidua and amnion is the chorion, which is a rich source of the 
prostaglandin degrading enzyme 15-hydroxyprostagladin dehydrogenase (PGDH) (15, 17). 
    Mediators of inflammation also appear to be involved in cervical ripening. These mediators 
include interleukin (IL-8) and monocyte chemotactic peptide (MCP-1) (16). PGE2 induces 
vasodilatation of cervical capillaries and this increases their permeability to neutrophils, which 
become drawn into cervical stroma, under chemotactic influence of IL-8(16). IL-8 also influences 












1.2.1 Induction agents and methods for inducing labour:  
There are several methods of cervical ripening, which indicates that there is no single universally 
acceptable or most effective method for cervical ripening and induction of labour. 
1.2.1(a) Misoprostol  
   Misoprostol is an agent that was initially designed for the treatment of peptic ulcer disease. 
As an unlicensed indication, misoprostol is now used in obstetrics and gynaecology for 
terminations of first and second trimester   pregnancies and induction of labour at term(18-20). 
It is a prostaglandin E1 analogue and has the advantage of being cheap, orally available, and stable 
at room temperature. In addition, it has a long shelf half life. It is also used for the prevention 
of postpartum haemorrhage (PPH) (21, 22). More than 45 randomized trials including 5400 women 
have found vaginal misoprostol to be more efficacious than oxytocin or prostaglandin E2 at 
effecting delivery within 24 hours(23, 24). There have been no significant differences in the 
frequency of serious adverse maternal or neonatal outcomes with low dose misoprostol compared 
with oxytocin or prostaglandin E2(23). Misoprostol can be given orally, vaginally, sublingually, 
buccally or rectally (25, 26). Misoprostol pharmacokinetics gives an idea of the different bio-
availabilities of the drug after various routes of administration. The pharmacokinetic profiles of 
the various routes of administration of misoprostol have been studied. After oral administration, 
misoprostol is rapidly and almost completely absorbed from the gastrointestinal tract (26, 27). 
However, it undergoes rapid and extensive first pass metabolism to form misoprostol acid (27).   
When given orally it peaks in 30 minutes and declines rapidly after 1 hour. Side effects of 




           Some studies show that the oral route of administration is less effective than vaginal in 
medical abortions and deliveries (26, 27).  This is in contrast with Uludag et al, who compared oral 
Misoprostol (100mcg) and vaginal misoprostol (50mcg) and found no significant differences in the 
mean induction to delivery interval, intra-partum complications and neonatal outcomes between 
the two groups (28). Although the peak concentration is higher after oral administration than for 
vaginal route, the “area under the curve” is higher when administered vaginally (26, 27). This 
means it has greater bio-availability vaginally and helps to explain why it is more effective for 
medical abortions. A pharmacokinetic study compared the absorption kinetics of oral, vaginal and 
sublingual routes of administration of misoprostol (26). It found that sublingual administration 
has the shortest time to peak concentration, the highest peak concentration and the greatest 
bio-availability compared to other routes. The study further showed that it takes 30 minutes to 
reach peak concentration after oral and sublingual administration and 75 minutes for vaginal 
route. The shape of the absorption curve after rectal administration is similar to the vaginal but 
its area under the curve is only a third of the vagina administration.  
          There are several possible regimes for misoprostol for induction of labour that are widely 
used. There is no evidence that any one of them is better than the other(29). One such regimen 
for oral misoprostol proposed by Hofmeyr is 20mcg 2hourly x 3 doses increased to 40mcg x 
3doses. The solution is made by dissolving 200mcg misoprostol in 200cc of water. This regimen 
has been adapted for IOL at LUDWMH as will be shown below. A systematic review of 
randomized trials comparing oral with vaginal routes of administration has found the oral route to 
be associated with slower labours but fewer C/S (23, 30). 
      Hofmeyr et al has submitted, after review of the evidence, that there is no certainty as to 
which route of administration is preferable. Misoprostol tablets as a whole or fractions may be 
swallowed without having to be dissolved in water for terminations of pregnancy and induction of 
labour(22). Earlier gestations would require higher doses than term pregnancies for successful 










Mean plasma concentration of misoprostol with respect to time.                
[Pharmacokinetics of different routes of administration of Misoprostol.] 








Adapted from Tang SO. Misoprostol: Pharmacokinetic profiles, effects on the Uterus 





1.2.1(b) Dosage of vaginal misoprostol  
      There are various regimens for the use of vaginal misoprostol and studies comparing lower 
doses of 25mcg with 50mcg showed no significant differences in caesarean and operative vaginal 
deliveries or incidences of tachysystole or hyperstimulation syndromes in the two groups studied 
(13, 32, 33). Neonatal outcomes were also similar. Use of the 50 mcg dose was reported to be 
associated with a greater proportion of deliveries within 24 hours, a greater proportion of 
patients delivering after a single dose, and the less frequent need for oxytocin augmentation(34).  
Uludag et al compared the safety and efficacy of oral misoprostol 100mcg 4hourly and 50mcg 
vaginal misoprostol up to 6 doses in 99 patients .There was a low incidence of failed inductions in 
both groups (4% versus 2.5%) respectively(28). 
1.2.1(c) Complications of misoprostol 
A. Uterine hyperstimulation 
      A systematic review has found vaginal misoprostol in the dosages used to be associated 
with more uterine hyperstimulation with non-reassuring fetal heart rate changes when 
compared to the use of PGE2 (26, 27, 35). Misoprostol was also more potent as a uterine 
stimulant in these trials but it was not established whether the effect was 








B. Meconium-stained liquor 
      Meconium-stained liquor is significantly more common with labour induction with 
misoprostol than with either vaginal or intra-cervical PGE2 (15). It has been postulated that 
certain myometrial stimulants may cross the placenta to stimulate fetal bowel smooth muscle and 
cause meconium passage (26). An alternative explanation for the increased meconium passed 
during misoprostol IOL is that the resistance of misoprostol to placental 15-hydroxyprostaglandin 
dehydrogenase enables more of the drug to enter the fetal circulation than doses of PGE2 (26). 
 
C. Precipitate delivery 
      Precipitate delivery (labour <2 hours) has been described as a possible complication of 
misoprostol induction at term (37). Oyelese et al describes a case of an extensive cervical 
laceration following rapid misoprostol-induced labour (37). The importance of precipitate delivery 












D. Ruptured uterus 
     There have been isolated reports of rupture of an unscarred uterus following 
misoprostol labour induction but without a reliable basis of comparison, it is unclear whether the 
reports  of uterine rupture following misoprostol induction is greater or less than with other 
methods of labour induction (37). 
Misoprostol has been used to induce labour in women with previous C/S (38). There have been 
several reports of uterine ruptures but there is no data from randomized control trials. Most 
authors recommend that misoprostol should not be used in women with uterine scars (38). 
E. Caesarean section 
 
    The relationship between misoprostol and C/S is not clear. Reports from studies show a 
tendency to increased C/S rates due to fetal heart rate abnormalities (6, 37, 39, 40). Despite 
increases in uterine hyperstimulation, most reviews and trials have shown no significant 











1.3.0 Vaginal prostaglandins 
     Labour induction with prostaglandin F2a was introduced in the 1960s. Subsequently, 
formulations of prostaglandin E2 were developed which largely replaced the use of F2a in 
countries such as the UK (31, 43). Prostaglandins in form of pessaries, tablets, gels and 
suppositories are in use and commonly inserted vaginally. A wide variety of dosages and dosing 
intervals are in use. A limiting factor for the use of prostaglandin E2 preparations in many 
countries has been the high cost of the agent (20). A systematic review of vaginal prostaglandin 
E2 compared with placebo or no treatment showed that prostaglandins were clearly effective in 
bringing about delivery within 24 hours (44, 45). PGE2 tablets (3 mg 6–8 hourly to a maximum 
dose of 6 mg) are recommended in preference to PGE2 gel (2 mg for nulliparous women with 
modified Bishop score of‹ 4, 1 mg to all others, repeated 6 hourly to a maximum dose of 4 mg(3). 
    The Royal college of obstetrics and gynaecology (RCOG) recommends the use of intravaginal 
PE2 irrespective of woman’s parity or cervical status. Systematic review of vaginal prostaglandin 
E2 compared with placebo or no treatment showed that prostaglandins were clearly effective in 
bringing about delivery [relative risk (RR) of failure to deliver within 24 hours 0.03, 95% CI 0.02-
0.05(3)]. Different dosing regimens and intervals are in use and their most important limiting 
factor is their cost. If oxytocin is used after PGE2, 6 hours should elapse after the last dose of 








1.3.1 Intra-cervical Prostaglandins 
     This involves inserting prostaglandins into the cervix in order to maximize local effect but no 
clear advantage over vaginal administration has been shown ((46-48). 
1.3.2 Extra amniotic Prostaglandins 
   PGE2 and PGF2α may be injected into the extra amniotic space via a Foley catheter as a solution 















1.3.3 Mechanical methods 
  These are the oldest methods of induction of labour. They include extra-amniotic Foley 
catheter and sweeping of the amniotic membranes or stretching of the cervix (50, 52). This 
results in the release of endogenous prostaglandins from the stimulation of the cervix and lower 
uterine segment (52, 53). They are associated with fewer incidences of uterine hyperstimulation 
and fetal heart rate changes and have similar effectiveness with vaginal PGE2. Sweeping 
membranes is associated with increased circulating prostaglandins and is used by some clinicians 
in combination with medical agents to curtail pregnancy (54, 55). Cromi at el evaluated maternal 
and fetal outcomes in a large series of patients undergoing IOL with extra-amniotic Foley 
catheter (56). The main outcome measures were clinical chorioamnionitis, endometritis, and 
suspected and culture-proven neonatal sepsis. The study concluded that trans-cervical use of the 
Foley catheter is safe for pre-induction cervical ripening and the associated risk of maternal or 












1.3.4 Extra amniotic saline infusion:  
The effect of Foley catheter on the cervix may be enhanced by the infusion of saline into the 
extra-amniotic space at 50ml/h (49, 57). Studies suggest that this method has similar efficacy to 
vaginal misoprostol 25mcg 4hourly(49) 
1.3.5 Amniotomy 
Rupturing of the amniotic membranes through the cervix has been documented as a 
Method of labour induction for over 200 years(16, 58, 59). The presumed mechanism of action is 
the release of endogenous prostaglandins, which in turn, may result in cervical changes and 
labour(60, 61). This method has the advantage that the use of exogenous uterine stimulants, with 
the problems of uterine hyperstimulation, is avoided, and the amniotic fluid may be observed. 
However there is an increased risk of ascending infection especially in background of HIV 

















1.3.6 Intravenous oxytocin 
    Traditionally, the use of oxytocin has been accompanied by amniotomy. 
According to Hofmeyr et al, the only trial comparing intravenous oxytocin alone versus placebo or 
expectant management for women with unfavourable cervix was in women with spontaneous 
rupture of the membranes. Vaginal delivery was greatly enhanced with oxytocin(64). However, 
oxytocin without amniotomy is significantly less effective than vaginal PGE2 for labour induction 
in women with unfavourable cervices (64). 
1.3.6(a) Adverse effects of oxytocin 
       Commonest side effect of oxytocin is uterine hyperstimulation. This may present as 
tachystole with more than 5 contractions in 10 minutes, contractions of more than 90 seconds 
duration or an increase in uterine tonus (65). The decreased intervillous blood flow associated 
with hyperstimulation ultimately leads to decreased oxygen transfer to fetus, with appearance of 
late decelerations(66). 
     Uterine rapture is a complication of inappropriate use of oxytocin. Retrospective series of 
uterine rupture have implicated oxytocin in 4.3% to 12.5% of occurrences (66). To avoid this 
complication it is advised to avoid use of oxytocin in grand multipara, to use internal uterine 
pressure monitoring for patients with previous caesarean delivery and avoiding it in obstructed 
labours(64, 65). Water intoxication is a complication of oxytocin and can be avoided by use of 













       This is more common in Asia for cervical ripening. One study demonstrated that acupuncture 
at points LI 4 (large intestine 4) and SP 6 (spleen 6) induces cervical ripening at term (16, 68). 
Acupuncture was also shown to decrease interval between estimated date of confinement and the 
actual time of delivery(68). 
2.0 Study Justifications 
     As noted above IOL is a common obstetric procedure and therefore requires a regular audit. 
This gives confidence that medical procedures are up to date, helps to modify existing practice 
or introduce new procedures. It is a form of confidence check and balance to ensure a continued 
delivery of high quality of health care 
    Misoprostol is the drug of choice for IOL at LUDWMH. Misoprostol is administered according 
to the protocol shown on the table below (Table A). Observations (by author) suggested a large 
number of patients who had repeat IOL and subsequently ended up with operative deliveries. This 
observation needed to be ascertained in empirical terms to determine its significance. It could 
modify or change existing practice.  Repeat audits of this kind, over years would give an idea of 









          Protocol for induction of labour at LUDWM hospital 
Gestation <29/40 29-36/4o 36+/40    










































Oral Misoprostol Oral Misoprostol Prostin E2 
1mg PV 6hrly 
AROM + 
Oxytocin 
Prev C/S Consult Specialist    
  
Oral Misoprostol regime consists of 200mcg in 200cc of water. Start with 20mls 2hourly x 3doses 








Misoprostol Table for Induction from Lower Umfolozi District War Memorial Hospital 






4.1 Induction and failed induction of labour: Induction of labour is a process of 
artificial stimulation of uterine contractions after age of fetal viability and before spontaneous 
onset of labour, with the aim of vaginal delivery(2). For the purpose of this study, failed IOL was 
failure to achieve vaginal delivery. This was the definition used by Chigbu et al (69). However 
analysis of data took into account the number of patients who delivered within 24 hours of 
initiation of IOL.  
4.2. Study Population- all patients who underwent IOL and delivered fetus with weight 
500grams or more. 
4.3 Study location; Lower Umfolozi District War Memorial (LUDWM) hospital is a regional 
hospital that serves as a referral hospital for 17 district hospitals and each of which  services 9-
14 clinics. All complicated obstetric cases are referred to LUDWM hospital. The monthly 
deliveries at the regional hospital are between 800 to 950. On average, there were 4 women per 
day undergoing IOL. Therefore about 960 women undergo IOL per year (9.6%). The hospital had 
a C/S rate which varies between 35-40% at the time of study. 
4.4: Study period: 8 months. The sample was derived from the period December 2009 to 
July 2010. This is the period that captured the desired number of patients. (See 4.5 below) 
4.5 Sample size- All patients undergoing IOL for various indications. The sample size was 
determined by available resources; with the aim to obtain a large enough sample to allow analysis 
of the subcategories of inductions of labour. The target was to recruit 500 women 





4.7 Inclusion criteria: All patients who underwent induction of labour in the study period with 
a fetal weight of 500grams or greater were included.  
4.8 Exclusion criteria: Women with clinical signs of infection were excluded because 
infection is a confounder for adverse fetal outcome. Files without basic essential details for IOL 
were also excluded. 
4.9 Data Collection Methods and Tools. The researcher went through all the files 
of patients who underwent IOL in the study period. These files were to be analysed by the 
researcher and the information was entered in a structured data sheet in the Excel computer 
programme. The researcher analysed data sheets from the Neonatal Intensive Care (NICU) to 
obtain perinatal outcomes and recorded them into the Excel programme. 
5.0 Statistical Planning- The data collected was captured and subsequently analysed using 
the Statistical Package for Social Sciences (SPSS version 18). Descriptive statistics such as 
frequencies and proportions was used to summarize data 













 5.2 Study limitations 
























5.3.1 Primary outcomes 
• Assess the indications for IOL 
• Examine pregnancy outcomes following IOL 
Maternal Outcomes 
• Number of normal vaginal deliveries (NVD) following IOL 
• Number of C/S following IOL 
• Number  who had repeat IOL 
Fetal outcomes 
• Neonatal outcomes which include: 
 Apgar score 
 NICU admissions,  








5.3.2 Secondary out comes 
• To determine induction delivery induction delivery intervals. 
• Use of oxytocin for augmentation of labour following induction. 
5.4 Regulatory approval 
5.5 Ethics Committee: Ethical approval was obtained from the Bioethical Research 
Committee of the University of KwaZulu-Natal (Ref BE018/11). Patients were not identified by 
their names but by study numbers. There were no patient identifiers recorded in the data 
collection sheets and the information obtained was kept in a lockable cupboard. The information 
was destroyed after data analysis.   
5.6 Hospital approval. Approval for the study was provided by the Hospital Chief 
Executive office 
















                                 Results 
    The total number of deliveries during the study period was 6649. The total deliveries included 
fetuses with weight above 500 grams.  30 files were excluded because of missing essentials 
details. There were 502 files that were analyzed.  The induction rate was 8%.The majority, 51.4 
%, were primigravidae and 47% were of parity 1-4. The descriptive characteristics of all patients 
who had IOL are shown in Table 1(Page 45). The table shows incomplete data documentation such 
as height and weight which is important for determination of body mass index (BMI) which has a 
bearing on the success or failure of IOL. The number of deliveries and number of inductions per 
month over the study period are shown on graph 1(page 41). Graph 2(page 47) shows the 
gestational age at IOL. Postdates accounted for 25.9% of IOL. Accurate dating by ultrasound 
scan is important to determine the time for IOL and graph 3[page 48] shows the gestational ages 
at time of first scan.  59.8% of patients did their first ultrasound after 27 weeks. Only 14.7% 
had their first ultrasound in the first trimester of pregnancy. 
     There were three major indications for IOL viz hypertensive disorders of pregnancy (43.6%), 
postdates (25.9%) and pre-labour rupture of membranes (14.7%) [ Table 2, page 49]. Among the 
hypertensive disorders of pregnancy, gestational hypertension (30.3%, N=152) and pre-eclampsia 
(13.3%, N=67) were the most common subcategories. 
     The commonest modes of IOL were oral misoprostol alone (63.5%) and vaginal misoprostol 




primigravidae (N=146) compared with 2.5% patients of parity 1-4 (N=6). There were 215 patients 
of parity 1-4 (91.1%) who received oral misoprostol compared with 101 primigravidae (39.1%). 
    Induction of labour resulted in 58.3% (N=293) of the patients successfully delivering vaginally 
and 40.2% undergoing C/S .The rest had assisted vaginal deliveries [1.4% (N=7)].  
  Table 2 [page 49] shows the modes of delivery following the various modes for IOL. 52% of all 
the patients who had vaginal misoprostol only (N=152) delivered vaginally while 48% had C/S. 
There was a 61.8 % vaginal delivery rate of all patients who were induced with oral misoprostol 
only (N=319).  
  Table 3 [page 50] shows the parity, mode of IOL and mode of delivery in relation to number of 
cycles of induction. 88.2% (N=443) delivered with one cycle of IOL. 47.8 %( N=240) of the 
primigravidae delivered with one cycle compared with 39% (N=196) of the multigravid1. There 
were 47 (9.3%) patients who had two cycles of IOL and 12 (2.3%) received 3 cycles of IOL. 
Induction with oral misoprostol alone accounted for 15% having repeat inductions (48 out of 319) 
compared with 3.4% who received vaginal misoprostol (5 out of 147). The repeat inductions were 
not associated with adverse maternal outcomes [Table6, page 53]. 
   Table 4 [page 51] shows the various indications for C/S. 13.1 % (N=66) had non reactive fetal 
heart recordings following the initiating IOL and prior to onset of labour and had caesarean 
delivery. Overall 56% (N=114) of the patients had C/S with associated CTG abnormalities. The 
table also gives the number of doses of the induction agents that were given. Oral misoprostol 
had the largest total number of doses administered (N=318) to induce labour compared to vaginal 




(N=249) compared with patients of parity 1-4 (N=228).  It must be observed on the second part 
of table 4 {page 51] that some patients did not complete a full of IOL but only one or a few doses 
of the full cycle before going into labour , while others went up to three full cycles.  
       Induction delivery interval is shown in Table 5[page 52]. Delivery within 24hours was 
achieved in 69.7% of the patient (N=350). Among this group, 63.7% (N=223) had normal vaginal 
deliveries and 34.8% (N=122) by C/S. There were 53.7% (N=188) primigravidae and 44.9% 
(N=157) multigravid1 who delivered within 24 hours. The mode of IOL for the patients who 
delivered within 24 hours was composed of 59.4% (N=208) who received oral misoprostol and 34% 
(N=120) who received vaginal misoprostol. There were 42.6% (N=149) of patients with 
hypertensive disorders of pregnancy, 25% (N=88) with post dates and 16% (N=57) with pre-
labour rupture of membranes who achieved delivery within 24 hours. 
      Table 6[page 53] shows maternal outcomes following IOL. Gastrointestinal side effects were 
documented in only 1% of patients. There were no serious maternal adverse effects directly 
related to use of misoprostol.  10 women (1.9%) had post partum haemorrhage and had full 
recovery. One woman (0.2%) had a laparatomy for puerperal sepsis. she had full recovery. 
       Fetal outcomes are shown in Table 6[page 53]. There were 34 admissions (6.7%) to neonatal 
ICU (NICU) following IOL. The table also depicts the weight distribution at birth. Their apgar 
scores were good (see graph 4, page 54).  One early neonatal death was documented. The leading 
causes for admissions to NICU were prematurity (10 =2%), hypoxic ischaemic encephalopathy 
(HIE) (9=1.8%) and congenital pneumonia (7=1.4%).   Convulsions occurred in 4 babies of the 9 
admitted to NICU for HIE. One of the 4 babies who convulsed ended up as an early neonatal 
death (ENND). The ENND was delivered by C/S for fetal distress, but the C/S was delayed for 2 
hours due to limited theatre facility at the time.  Analysis of the other babies with HIE and 
convulsions did not reveal avoidable factors. However all recovered and were discharged.  







                                              Discussion 
     Our study shows that rate of IOL at LUDWMH during the study period was 8% (see flow 
chart ). The rate is similar to the one by Mbele et al of 9.6%(1). Our findings are also in keeping 
with the  world wide range for IOL of 3 to 30%(70).  
   The study showed that hypertensive disorders of pregnancy were an important indication for 
IOL. 42.2% (N=109) of the primigravidae had hypertensive disorders of pregnancy. The study by 
Mbele at el  showed that women with low cervical scores (<5)  having IOL in their first pregnancy 
have higher C/S rates when compared with multiparous women (1).The overall C/S rate for 
nulliparous women  in the current study was 49.2%. 
   The concept of failed IOL is controversial. However, women must be counselled of this 
possibility and the chances of a C/S. Further, failed IOL must be differentiated from failure to 
progress in labour and from cephalo-pelvic disproportion or malposition.  There are a variety of 
definitions.  In general terms failed IOL means the woman does not enter active labour or the 
cervical score does not improve or the cervix does not dilate more than 3cm over a 12 hour period 
of ruptured membranes and good uterine activity(74). This study adopted Chigbu’s definition of 
failed IOL as failure to achieve vaginal delivery (68). It must be noted however that failed IOL is 
not necessarily an indication for C/S. Each case must be re-assessed clinically and the indications 
for induction reviewed in relation to harms and benefits to mother and fetus. All being well 
consideration should be given to repeat attempt of IOL at a variable period of time. Women must 




   The 3 main indications for IOL were hypertensive disorders of pregnancy (43.6%), postdates 
(25.9%) and pre-labour rupture of membranes (14.7%). These were also the 3 main indications for 
IOL found by Mbele et al in their study in Kalafong , South Africa(1).In their study delivery 
within 24 hours was achieved in 52.4% of patients and the C/S rate was 42.1%. Our study  showed 
a similar outcomes: out of the 502 study patients, 58.3% had normal vaginal birth and 40.2% had 
C/S. Delivery within 24hours was achieved in 69.7% of the study patients [Table 5, page 52].This 
group was composed of 45.4%(N=228) who delivered vaginally and 24.3% (N=122) who had C/S. 
Another 20.3% (C/S=58 and normal birth=44) of the participants delivered after 24hours but 
within 48hours. 
      Uncertainty exists over the need to induce labour for patients with mild hypertension/pre 
eclampsia who have stable maternal and fetal conditions at 34 -37 weeks. However, the HYPITAT 
study evaluated  maternal and neonatal complications in patients with pregnancy induced 
hypertension/ pre eclampsia at 36 to 40 weeks and the result of this randomised  trial revealed 
that IOL at or after 37 weeks was associated with lower rates of maternal complications without 
increased C/S rates or neonatal complications(71). 
    It is reported that 20% of pregnant women will require IOL, which usually requires more than 
one intervention and will present challenges to clinicians, health care workers and mothers(72). 
Our study showed that 9.3% (N=47) had 2 attempts at IOL and 2.3% (N=12) had 3.The use of  
oral misoprostol had the largest number of women who had repeat attempts at IOL compared to 
vaginal misoprostol [Table 3, page 50]. It has been reported that vaginal misoprostol is more 




eliminated more rapidly (2-3hours) than vaginal misoprostol (≥4hours)(24). Other factors which 
may affect delivery induction interval include maternal ethnicity, maternal weight, body mass 
index (BMI) and age, gestational age and fetal weight(73).  Our study did not analyse these 
factors. Furthermore, being a retrospective study there was poor or lack of documentation of 
certain parameters such as bishop score, and maternal height.  
  There were 13.1% (N=66) of study patients who developed non reactive fetal heart recordings 
following IOL before active labour and had C/S. The number consists of 41 primigravidae, 24 
multigravid1 and 1 multigravid2. Subgroup analysis of this number cannot yield meaningful 
conclusions and therefore a larger study with more numbers would be required. But non reactive 
traces call for the need to weigh up risks and benefits  for IOL and extensive counselling of 
patients before embarking on the procedure(3). Other convenient, relatively cheap and safe 
methods are not used because the induction protocol table 3[page 50] is stuck on the wall in 
labour at the hospital and readily comes to the mind of health care worker. Only one patient had 
amniotomy alone for IOL and analysis indicates she was of high parity and caution was exercised 
to avoid uterine rupture by not administering oxytocin. 
    The 5 minutes apgar scores for the new born were good [Graph 4, page 54]. There was a 6.7% 
admission to NICU.  There was no serious maternal adverse incident directly associated with IOL 
[Table 6, page 53]. Side effects of misoprostol of fever, pyrexia and diarrhoea were not 
observed as reported in literature. Hofmeyr et al report that 30-40% of patients under a 
controlled trial who undergo IOL will show these side effects of misoprostol(3). In practice these 




                                   
 
                                                   Summary 
1. IOL had a normal vaginal delivery rate of 58.3% and 1.4% assisted vaginal delivery rate during 
the study period. Delivery within 24hours was achieved in 69.7% (N=350) and a further 20.3% 
(N=102) within 48hours. There were 202 patients (40.2%) who delivered by C/S for various 
indications. There were no serious maternal adverse outcomes documented following IOL. 
2. There were 47 (9.3%) patients who had two cycles of misoprostol and 12 (2.3%) received 3 
cycles misoprostol inductions. More audits required to see the trends in repeat inductions. The 
repeat inductions were not associated with adverse maternal outcomes. 
3. Oxytocin was used to augment labour in 8.2% of participants (N=41). 23 patients were 
augmented following IOL with oral misoprostol alone, 14 patients following vaginal misoprostol 
alone and the rest from other modes of IOL. 
4. The IOL protocol for LUDWMH was not followed in 17.7% of patients (N=89) and reasons were 
not documented. These resulted in following: 
4.1 One cycle of induction=70 
4.2 Two cycles of induction=13 
4.3 Three cycles of induction=6 
5. There were 34 admissions (6.7%) to neonatal ICU (NICU) following IOL. Their apgar scores 
were good (see graph 4, page 54) with only one early neonatal death. The leading cause for 
admissions to NICU were prematurity (10 =2%), hypoxic ischaemic encephalopathy (HIE) (9=1.8%) 
and congenital pneumonia (7=1.4%). There were 6 babies ventilated in NICU following IOL and 






                                   Conclusion 
The indications for IOL and induction rate in this study were similar to those reported by Mbele 
et al in Kalafong hospital, another regional hospital in South Africa. The vaginal deliveries and C/S 
rates were also similar to the Mbele study.  
 
                                      Recommendations 
1. More audits required to see trends in IOL. 
2. Current methods of IOL must continue. They have a good success rate and have no 
documented serious adverse maternal or fetal outcomes. 
3. Bishop’s score should be inscribed in the antenatal cards with all required components so 
that during IOL, medical officer simply have to enter the scoring numbers. This will be 
similar to partograph in antennal cards where medical officers simply enter examination 
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Descriptive  Characteristics of women who had IOL /N=502 
Age in years  Frequency Percentage 
1 ≤20 136 27 
2 21-30 264 52.6 
3 31-40 92 18.3 
4 ≥40 10 2 
Race    
1 Black 490 97.6 
2 Non Black 12 2.4 
Parity    
1  Primigravidae 258 51.4 
2 Multigravida1(parity 1-4) 236 47 
3 Multigravida2( Parity >4) 8 1.6 
Weight    
1 Weight documented 498 99.2 
2 Weight not documented 4 0.8 
Height    
1 Height documented 200 38.9 
2 Height not documented 302 60.1 
Bishop Score Documented 0 0 
Cervical assessment Documented 502 100 
HIV Status    
1 HIV Negative 338 67.3 
2 No data 1 0.2 
3 Started HAART 8 1.6 
4 On HAART prior to pregnancy 45 9 





























              Flow chart for IOL 
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This graph shows how early the participants booked for ultrasound scan as accurate 












Indications for IOL, Mode of IOL, Mode of delivery  and Parity Cross tabulation 
 Parity 
Indications for IOL Primigravidae Multigravid1 Multigravid2 Total 
Postdate 69 (26%) 61 (25.8%) 0 (0%) 130 (25.9%) 
Hypertensive disorders of pregnancy 109 (42.2%) 106 (44.9%) 4 (50%) 209 (41.6%) 
Intra-Uterine fetal death 7 (2.7%) 9 (3.8%) 0 (0%) 16 (3.2%) 
Prolonged latent phase 14 (5.4%) 9 (3.8%) 1 (12.5%) 24 (4.8%) 
Oligohydramnios 8 (3.1%) 5 (2.1%) 2 (25%) 15 (3%) 
Decreased fetal movements 1 (0.4%) 2 (0.8%) 0 (0%) 3 (0.6%) 
Unclear indication 0 (0%) 1 (0.4%0 0 (0%) 1 (0.2%) 
Pre-labour rupture of membranes 39 (15.1%) 35 (14.8%) 0 (0%) 74 (14.7%) 
Intra-Uterine growth restriction 7 (2.7%) 4 (1.7%) 0 (0%) 11 (2.2%) 
Diabetes Mellitus 0 (0%) 3 (1.3%) 1 (12.5%) 4 (0.8%) 
 social indications 4 (1.6%) 1 (0.4%) 0 (0%) 2 (0.4%) 
Total 258 (100%) 236 (100%) 8 (100%) 502 (100%) 
Mode of IOL     
Vaginal misoprostol alone 146 (56.6%) 6 (2.5%) 0 (0%) 152 (30.3%) 
Oral misoprostol alone 101 (39.1%) 215 (91%) 3 (37.5%) 319 (63.5%) 
ARM followed by oxytocin 5 (1.9%) 4 (1.7%) 0 (0%) 9 (1.8%) 
Sweeping membranes followed by 
oxytocin 
0 (0%) 1 (0.4%) 0 (0%) 1 (0.2%) 
Foley catheter followed by oxytocin 0 (0%) 1 (0.4%) 0 (0%) 1 (0.2%) 
Foley catheter 0 (0%) 19 (8%) 1 (12.5%) 2 (0.4%) 
Prostin alone 1 (0.4%) 4 (1.7%) 2 (25%) 7 (1.4%) 
Vaginal misoprostol followed by oral 
misoprostol 
2 (0.8%) 0 (0%) 0 (0%) 2 (0.4%) 
Oral misoprostol and sweeping 
membranes 
0 (0%) 3 (1.3%) 0 (0%) 3 (0.6%) 
Oral misoprostol followed by 200mcg vaginal 
misoprostol start 
0 (0%) 1 (0.4%) 0 (0%) 1 (0.2%) 
Oral misoprostol followed by Prostin 0 (0%) 0 (0%) 1 (12.5%) 1 (0.2%) 
Oxytocin 3 (1.2) 0 (0%) 0 (0%) 3 (0.6%) 
Amniotomy alone 0 (0%) 0 (0%) 1 (12.5%) 1 (0.2% 
Total 258 (100%) 236 (100%) 8 (100%) 502 (100%) 
Mode of Delivery     
Normal birth 126 (48.8%) 165 (70%) 2 (25%) 293 (58.4%) 
C/S  127 (49.2%) 71 (30%) 4 (50%) 202 (40.2%) 
Forceps 2 (0.8%) 0 (0%) 0 (0%) 2 (0.4%) 
Vacuum 3 (1.2%) 0 (0%) 2 (25%) 5 (1%) 
Total 258 (100%) 236 (100%) 8 (100%) 502 
     
 
 





Mode of delivery, Parity, Mode of IOL  and number of Cycles of induction Cross tabulation 
 Number of Cycles of IOL 





Mode of delivery N=443 N=47 N=12 502 
1.Vacuum 5 (1.1%) 0 (0%) 0 (0%) 5 (1%) 
2.Forceps 2 (0.5%) 0 (0%) 0 (0%) 2 (0.4%) 
3.C/S 169 (38.1%) 28 (59.6%) 5 (41.7%) 202 (40.2%) 
4.NVD 267 (60.3%) 19 (40.4) 7 (58.3%) 293 (58.3%) 
Parity     
1.Primigravidae 240 (54.2%) 16 (34%) 2 (16.7%) 258 (51.4%) 
2.Multigravid1 196 (44.2%) 31(66%) 9 (75%) 236 (47%) 
3.Multigravid2 7 (1.6%) 0 (0%) 1 (8.3) 8 (1.6%) 
Mode of IOL     
1.Oral misoprostol alone 271 (61.2%) 40 (85.1%) 8 (66.7%) 319 (63.5%) 
2.Vaginal misoprostol alone 147 (33.2%) 5 (10.6%) 0 (0%) 152 (30.3%) 
3.Amniotomy alone 1 (0.2%) 0 (0%) 0 (0%) 1 (0.2%) 
4.Oxytocin 3 (0.7%) 0 (0%) 0 (0%) 3 (0.6%) 
5.Oral misoprostol followed by 
Prostin 
0 (0%) 0 (0%) 1 (8.3) 1 (0.2%) 
6.Oral misoprostol and 200mcg PV 
Start 
0 (0%) 1 (2%) 0 (0%) 1 (0.2%) 
7.Oral misoprostol followed 
sweeping membranes 
1 (0.2%) 0 (0%) 2 (16.7%) 3 (0.6%) 
8.Vaginal misoprostol followed 
by oral misoprostol 
0 (0%) 1(2%) 1 (8.3%) 2 (0.4%) 
9.Prostin alone 7 (1.6%) 0 (0%) 0 (0%) 7 (1.4%) 
10.Foley Catheter 2 (0.5%) 0 (0%) 0 (0%) 2 (0.4%) 
11.Foley Catheter followed by 
oxytocin 
1 (0.2%) 0 (0%) 0 (0%) 1 (0.2%) 
12.Sweeping membranes 
followed by Oxytocin 
1 (0.2%) 0 (0%) 0 (0%) 1 (0.2%) 
13.ARM followed by oxytocin 9 (2%) 0 (0%) 0 (0%) 9 (1.8%) 












CTG: Cardiotocography, C/S: caesarean section, CPD: cephalo-pelvic disproportion, IOL: induction of 
labourMultigravidae1+parity 1-4, Multigravidae2+ Parity > 4 
      Table 4 
 
Indications for C/S, Number of doses of induction agents and Parity Cross tabulation 
Indication for C/S Parity 
Primigravidae Multigravida1 Multigggravida2 Total 
CTG abnormality but not in labour 41 (32%) 24 (33.8%) 1 (25%) 66 (32.7%) 
Fetal distress/CT G abnormalities in labour 43 (33.8%) 11 (15.5%) 0 (0%) 54(26.7%) 
Development of eclampsia 3 (2.4%) 0 (0%) 0 (0%) 3 (1.5%) 
Development of pre-eclampsia 0 (0%) 3 (4.2%) 0 (0%) 3 (1.5%) 
Failed IOL     
1.One cycle IOL 3 (2.4%) 7 (9.9%) 2 (50%) 12 (6%) 
2.Two cycle IOL 4 (3.1%) 6 (8.5%) 0 (0%) 10 (5%) 
3.Three cycle IOL 1 (0.8%) 3 (4.2%) 0 (0%) 4 (2%) 
CPD 24 (18.9%) 5 (7%) 1 (25%) 30 (15%) 
Poor cervical dilatation despite oxytocin 6 (4.7%) 7 (9.9%) 0 (0%) 13 (6.4%) 
Other indications for C/S 2 (1.6%) 5 (7%) 0 (0%%) 7 (3.5%) 
Total 127 (100%) 71 (100%) 4 (100%) 202 (100%) 
Number of doses of induction 
agents(Excluding Foley catheter &Oxytocin) 
    
1 16 (6.4%) 3 (1.3%) 1 (16.7%) 20 (4.1%) 
2 63 (25.3%) 13 (5.7%) 0 (0%) 76 (16%) 
3 50 (20%) 25 (11%) 2 (33.3%) 77 (16%) 
4 51 (20.5%) 26 (11%) 0 (0%) 77 (16%) 
5 3 (1.2%) 19 (8.3%) 0 (0%) 22 (4.6%) 
6 45 (18%) 96 (42%) 2 (33.3%) 143(29.6%) 
7 1 (0.4%) 2 (0.9%) 0 (0%) 3 (0.6%) 
8 2 (0.8%) 2 (0.9%) 0 (0%) 4 (0.8%) 
9 2 (0.8%) 2 (0.9%) 0 (0%) 4 (0.8%) 
10 1 (0.4%) 2 (0.9%) 0 (0%) 3 (0.6%) 
11 1 (0.4%) 0 (0%) 1 (16.7%) 2 (0.4%) 
12 12 (4.8%) 29 (12.7%) 0 (0%) 41 (8.4%) 
13 1 (0.4%) 1 (0.4%) 0 (0%) 2 (0.4%) 
14 0 (0%) 1 (0.4%) 0 (0%) 1 (0.2%) 
17 0 (0%) 3 (1.3%) 0 (0%) 3 (0.6%) 
18 1 (0.4%) 3 (1.3%) 0 (0%) 4 (0.8%) 
19 0 (0%) 1 (0.4%) 0 (0%) 1 (0.2%) 
Total 249 (100%) 228 (100%) 6 (100%) 483 (100%) 
     
     






                                                 Induction delivery interval 
                         Time 
Parity ≤24hours 24.1-47.9hours ≥48hours Total 
Primigravidae 188(53.7%) 49(48%) 21(42%) 258 
Multigravida1 157(44.9%) 53(52%) 26(52%) 236 
Multigravida2 5(1.4%) 0(0%) 3(6%) 8 
Total 350(100%) 102(100%) 50(100%) 502 
Mode of IOL     
Oral misoprostol alone 208(59.4%) 75(73.5%) 36(72%) 319 
Vaginal misoprostol alone 120(34.2%) 25(24.5%) 7(14%) 152 
Other modes of IOL 22(6.3%) 2(0.2%) 7(14%) 31 
 Total 350(100%) 102(100%) 50(100%) 502 
Indications for IOL     
Hypertensive disorders of pregnancy 149(42.6%) 47(46%) 23(46% 219 
Post dates 88(25%) 28(27.4%) 14(14%) 130 
Pre-labour rupture of membranes 57(16.2%) 13(12.7%) 4(8%) 74 
Other indications for IOL 56(16%) 14(13.7%) 9(18%) 79 
Total 350(100%) 102(100%) 50(100%) 502 
Mode of delivery     
Normal birth 223(63.7%) 43(42.2%) 27(54%) 293 
C/S 122(34.8%) 58(56.8%) 22(44%) 202 
Vacuum 3(0.9%) 1(0.1%) 1(2%) 5 
Forceps 2(0.6%) 0(0%) 0(0%) 2 
Total 350(100%) 102(100%) 50(100%) 502 
 











Maternal and fetal outcomes following IOL/ N=502 
Maternal outcomes Frequency Percentage 
1.Pyrexia 2 0.4 
2.Shivering 2 0.4 
3.Nausea/Vomiting/diarrhoea 5 1 
4.Primary PPH 8 1.6 
5.Secondary PPH 2 0.4 
6.Perineal tears 51 10.2 
7.Episiotomy 79 15.7 
8.Puerperal sepsis 3 0.6 
9.Laparatomy 1 0.2 
10.Retained Placenta 5 1 
11.Ruptured Uterus 0 0 
12.Maternal death 0 0 
Fetal outcomes   
1.Neonatal ICU admissions 34 6.7 
2.Recession 1 0.2 
3.Cyanosis 1 0.2 
4.Meconium exposed 1 0.2 
5.Low APGAR 5 1 
6.Congenital pneumonia 7 1.4 
7.HIE ( 4 Convulsions, 1 ENND) 9 1.8 
8.Prematurity 10 2 
Fetal weight(grams)   
500-1000 11 2.2 
1001-1499 10 2 
1500-2499 73 14.5 
2500-3499 305 60.5 
3500-4499 102 20.3 
≥4500 1 0.2 
   
   
 
1. ENND=Early neonatal death 2.HIE=Hypoxic ischaemic encephalopathy 3.PPH=Postpartum heamorrhage 
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